Novel NPY2R Agonist: Synergistic Anti-Obesity Effect With Existing Drugs
Novel NPY Y2 receptor agonist BI 1820237 showed synergistic anti-obesity efficacy when combined with existing weight loss agents, targeting a new peptide receptor for weight management.
Quick Facts
What This Study Found
Novel NPY Y2 receptor agonist BI 1820237 showed synergistic anti-obesity efficacy when combined with existing weight loss agents, targeting a new peptide receptor for weight management.
Key Numbers
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Novel NPY Y2 receptor agonist BI 1820237 showed synergistic anti-obesity efficacy when combined with
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.
- Published In:
- Molecular metabolism, 99, 102205 (2025)
- Authors:
- Augustin, Robert(2), Oldenburger, Anouk, Baader-Pagler, Tamara, Zimmermann, Tina, Borghardt, Jens, Hecksher-Sørensen, Jacob, Baljuls, Angela, Reindl, Wolfgang, Krawczyk, Bartlomiej, Martel, Eric, Brennauer, Albert, Peters, Stefan, Grube, Achim, Rudkjaer, Lise Biehl, Haebel, Peter
- Database ID:
- RPEP-10015
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Novel NPY Y2 receptor agonist BI 1820237 showed synergistic anti-obesity efficacy when combined with existing weight loss agents, targeting a new peptide receptor for weight management.
How reliable?
Consult publication.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10015APA
Augustin, Robert; Oldenburger, Anouk; Baader-Pagler, Tamara; Zimmermann, Tina; Borghardt, Jens; Hecksher-Sørensen, Jacob; Baljuls, Angela; Reindl, Wolfgang; Krawczyk, Bartlomiej; Martel, Eric; Brennauer, Albert; Peters, Stefan; Grube, Achim; Rudkjaer, Lise Biehl; Haebel, Peter. (2025). Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.. Molecular metabolism, 99, 102205. https://doi.org/10.1016/j.molmet.2025.102205
MLA
Augustin, Robert, et al. "Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.." Molecular metabolism, 2025. https://doi.org/10.1016/j.molmet.2025.102205
RethinkPeptides
RethinkPeptides Research Database. "Novel NPY2R agonist BI 1820237 provides synergistic anti-obe..." RPEP-10015. Retrieved from https://rethinkpeptides.com/research/augustin-2025-novel-npy2r-agonist-bi
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.